Merck’s TROP2 ADC Improves Survival in Phase 3 Gastroesophageal Cancer Trial
By Dr. Zubair Khalid, DVM, MS, PhD ·

Merck & Co. announced that its antibody-drug conjugate sacituzumab tirumotecan has improved overall survival in a phase 3 clinical trial for gastroesophageal cancer. The TROP2-directed ADC achieved a statistically significant survival benefit, marking the second global pivotal victory for the drug candidate.
The trial evaluated sacituzumab tirumotecan in patients with advanced or metastatic gastroesophageal cancer. The results met the primary endpoint of overall survival compared to standard-of-care therapy. Merck did not disclose specific survival data in the announcement.
Gastroesophageal cancer is an aggressive malignancy with limited treatment options after first-line therapy. The positive phase 3 result positions sacituzumab tirumotecan as a potential new option for patients in this setting.
Why This Matters
TROP2 is a cell-surface protein overexpressed in many solid tumors, making it an attractive target for antibody-drug conjugates. ADC technology links a cancer-killing drug to an antibody, delivering chemotherapy directly to tumor cells while sparing healthy tissue. If approved, this drug would join a growing class of TROP2-directed therapies that have already demonstrated efficacy in breast and other cancers. The success in gastroesophageal cancer, a notoriously hard-to-treat disease, represents a meaningful step forward for precision oncology and expands the potential of ADCs beyond more common tumor types.
Source: original report